Invivyd (IVVD) Rockets Over 50% Pre‑Market on November 14, 2025 as Traders Rush Into COVID Antibody Play

Invivyd, Inc. (NASDAQ: IVVD) is back in the spotlight this Friday, November 14, 2025, with its stock exploding higher in pre‑market trading on the back of building momentum around its COVID‑19 antibody franchise and recent earnings.

By early morning, IVVD was one of the most actively watched biotech names on Wall Street.

Invivyd stock today: IVVD among top pre‑market gainers

Multiple market data sources show Invivyd staging a huge move before the opening bell:

Around 6:45 a.m. ET, RTTNews’ “Morning Market Movers” column flagged IVVD up about 42% at $2.52 in pre‑market trading. ^[1]
By 7:06 a.m. ET, Benzinga’s “12 Health Care Stocks Moving in Friday’s Pre‑Market Session” listed Invivyd at $2.69, up roughly 52%, and highlighted a market cap of around $370 million. ^[2]
A follow‑up RTTNews piece published at 7:43 a.m. ET showed the rally accelerating, with IVVD up 58% at $2.80. ^[3]
MarketBeat’s “News Today” dashboard and Investing.com pre‑market data both show IVVD trading near $2.51 in extended hours, about 42% above Thursday’s close of $1.77 as of ~8:23 a.m. ET. ^[4]
StockTitan’s live IVVD overview page records a quote of $2.47, up 39.4% on the session at 08:08, with a 1‑year share price gain close to 99%. ^[5]

In short, Invivyd stock is up roughly 40–60% in Friday’s pre‑market session, depending on the venue and timestamp, after closing at $1.77 on November 13.

Notably, there is no new company press release dated November 14, 2025 on Invivyd’s own investor relations site; the latest formal update remains the Q3 2025 results and business highlights released on November 6. ^[6]

That strongly suggests today’s move is being driven by momentum, technicals and follow‑through from earlier news rather than a fresh headline this morning.

Today’s headlines about Invivyd (IVVD) – November 14, 2025

Here are the key IVVD‑related news items dated November 14, 2025:

RTTNews – “Morning Market Movers: CDTX, BCG, IVVD, TSSI See Big Swings” (7:04 a.m. ET)
Lists Invivyd among the top pre‑market gainers, up 42% at $2.52 in early trading. ^[7]
RTTNews – “Pre Market Movers: CDTX, IVVD, NVNO Swing Big” (7:43 a.m. ET)
Updates the move and shows IVVD up 58% at $2.80, placing it firmly in the “in the green” biotech cohort. ^[8]
Benzinga – “12 Health Care Stocks Moving In Friday’s Pre‑Market Session” (7:06 a.m. ET)
Ranks Invivyd among the day’s top healthcare gainers, with the stock up about 52% to $2.69 and a market cap estimate of $370.5 million. ^[9]
StockTitan – “IVVD – Invivyd Latest Stock News & Market Updates” (live, last updated 08:08)
Shows IVVD at $2.47 (+39.41%), cites 1‑year performance of 98.88%, and compiles the key recent press releases and SEC filings (Q3 results, IND clearance, management changes, etc.). ^[10]

Together, these pieces paint a consistent picture: Invivyd has become one of the most aggressive movers in U.S. healthcare trading today.

Why is Invivyd (IVVD) surging? Context from Q3 and the pipeline

Because no new corporate announcement hit the tape today, investors are largely reacting to a cluster of earlier catalysts that have been repriced aggressively over the past few weeks:

Q3 2025 earnings and revenue growth
Regulatory progress and data for the next‑generation COVID‑19 antibody VYD2311
Analyst upgrades and higher price targets
Rising short interest, creating potential for a squeeze

Let’s unpack each.

Q3 2025: revenue climbing, losses narrowing

Invivyd reported Q3 2025 financial results on November 6, 2025:

Net product revenue (primarily PEMGARDA) came in at $13.1 million, up from $9.3 million in the same quarter last year — roughly 41% year‑over‑year growth. ^[11]
Total revenue matched product revenue at $13.1 million in the quarter. ^[12]
Research & development (R&D) expense dropped sharply to roughly $8.0 million from about $57.9 million a year earlier, reflecting a shift from earlier heavy development spending and one‑time items. ^[13]
Selling, general and administrative (SG&A) costs increased modestly to about $15.0 million from $13.0 million, consistent with commercial build‑out. ^[14]
Net loss narrowed dramatically to around $10.5 million (or $0.06 per share) versus $60.7 million (or $0.51 per share) in Q3 2024. ^[15]

On the balance sheet side:

Invivyd ended Q3 with approximately $85.0 million in cash and cash equivalents, up from about $69.3 million at December 31, 2024. ^[16]
Stockholders’ equity rose to roughly $93.1 million from $67.5 million at year‑end 2024. ^[17]

StockTitan’s fundamentals dashboard shows trailing‑12‑month revenue of about $25.4 million and a TTM net loss near $170 million, translating to TTM EPS of roughly –$1.43 and deeply negative net and operating margins. ^[18]

So while the P&L trend is improving, Invivyd remains a loss‑making, high‑risk biotech with significant cash burn and a business heavily dependent on the trajectory of COVID‑19 and regulatory decisions.

PEMGARDA and VYD2311: the COVID‑19 antibody strategy

Invivyd’s investment story hinges on two closely related monoclonal antibodies:

PEMGARDA (pemivibart)

PEMGARDA is Invivyd’s earlier monoclonal antibody product, authorized in the U.S. under Emergency Use Authorization (EUA) since March 2024 for pre‑exposure prophylaxis of COVID‑19 in certain immunocompromised patients. ^[19]
The EUA is conditional: it only applies while variant susceptibility remains above a defined threshold (the combined frequency of variants with substantially reduced susceptibility must stay at or below 90%). ^[20]

PEMGARDA revenue is the backbone of Invivyd’s current commercial business — and the Q3 revenue growth suggests ongoing uptake in the immunocompromised population.

VYD2311 – a potential “vaccine‑alternative” antibody

Invivyd is pushing hard on VYD2311, a next‑generation COVID‑19 monoclonal antibody designed to act as a “vaccine‑alternative” with more durable protection:

In earlier Phase 1/2 data, VYD2311 showed an excellent safety profile across IV, subcutaneous and intramuscular dosing, with only mild to moderate adverse events reported. ^[21]
The intramuscular dose displayed a serum half‑life of about 76 days, suggesting the potential for multi‑quarter protection, which could exceed the durability of many current vaccines. ^[22]
VYD2311 shares >99% structural similarity with pemivibart, but is engineered for improved potency and resistance to newer SARS‑CoV‑2 lineages. ^[23]

On the regulatory front:

On October 6, 2025, Invivyd announced that the U.S. FDA cleared its IND and aligned with the company on a pivotal clinical program for VYD2311, with two Phase 3 trials — DECLARATION and LIBERTY — expected to launch around year‑end 2025. ^[24]
A separate August 14, 2025 press release detailed FDA alignment on a rapid pathway to a full Biologics License Application (BLA) for VYD2311 intended to protect U.S. adults and adolescents from COVID‑19. ^[25]
StockTitan’s event calendar now points to top‑line Phase 3 data for VYD2311 between May and August 2026, a key potential catalyst window. ^[26]

Invivyd has also formed and supported the SPEAR Study Group, which is exploring antibodies like PEMGARDA and VYD2311 in Long COVID and post‑vaccination syndromes, further broadening the addressable market if the data cooperate. ^[27]

All of this has contributed to a growing “non‑vaccine COVID therapy” narrative around the stock — a theme highlighted in recent coverage that saw IVVD surge on hopes of a durable, antibody‑based alternative to vaccination. ^[28]

Analyst views and price targets: high upside, high risk

The sell‑side and independent analysts are split but increasingly engaged:

StockAnalysis data show five analysts covering Invivyd with an average 12‑month price target of about $6.11 and an overall “Strong Buy” consensus — implying well over 200% upside from the pre‑rally share price. ^[29]
H.C. Wainwright recently doubled its IVVD price target from $5 to $10 while maintaining a buy rating, citing the company’s COVID‑19 antibody program and regulatory progress. ^[30]
Cantor Fitzgerald has also reiterated a bullish stance on Invivyd in early November, reaffirming a buy‑leaning rating. ^[31]

Yet not everyone is enthusiastic:

MarketBeat’s news feed shows that Weiss Ratings assigned IVVD a “Sell”‑level letter grade (e.g., “E+” or “D‑”) at various points in October and November, reflecting concerns about balance‑sheet risk, volatility and execution. ^[32]

In other words, IVVD is highly controversial: some analysts see extreme upside if VYD2311 succeeds, while others remain wary of cash burn and regulatory uncertainty.

Short interest and the potential for a squeeze

Another ingredient in today’s sharp move may be short covering.

MarketBeat data indicate that short interest in Invivyd increased by about 156.9% in October 2025, signaling that a growing number of traders had been betting against the stock. ^[33]

When a heavily shorted biotech with binary clinical and regulatory risks suddenly gaps higher, those short positions can be forced to buy back shares rapidly, amplifying the rally.

While we can’t quantify exactly how much of today’s spike is pure short squeeze versus new buying, the combination of:

strong Q3 revenue growth,
breakthrough‑style COVID antibody headlines,
an aggressive analyst target of $10 per share, and
elevated short interest

creates fertile ground for the kind of 40–60% pre‑market jump we’re seeing on November 14.

What Invivyd investors should watch next

For readers following IVVD on Google News or Discover, the next key checkpoints include:

Regulatory & clinical milestones
- Initiation of the DECLARATION and LIBERTY Phase 3 trials for VYD2311 around year‑end 2025. ^[34]
- Ongoing FDA interactions on a BLA pathway for VYD2311, including any updates to the expected timeline. ^[35]
- Future updates from the SPEAR Study Group on Long COVID and antibody‑based approaches. ^[36]
Commercial execution
- Trends in PEMGARDA revenue as physicians and immunocompromised patients navigate evolving COVID variants and competing options. ^[37]
- Any changes to the EUA status for PEMGARDA as variant dynamics shift.
Financial runway
- Cash usage versus the ~$85 million cash balance reported at the end of Q3 2025, and any additional equity raises or partnerships needed to fund Phase 3 VYD2311 trials through 2026. ^[38]
Analyst and sentiment shifts
- New or revised price targets and ratings, especially in response to today’s spike. ^[39]
- Changes in short interest, which could either fuel further squeezes or unwind as the stock stabilizes. ^[40]

Risks to keep in mind

Invivyd’s own filings and press releases emphasize several important risks:

The company is still loss‑making, with a large accumulated deficit and negative profit margins. ^[41]
The EUA for PEMGARDA could be revised or revoked if epidemiological or regulatory conditions change. ^[42]
The success of VYD2311 is not guaranteed: Phase 3 trials may yield weaker‑than‑expected data, delayed timelines, or safety signals that affect approval prospects. ^[43]
Invivyd may need additional financing, potentially diluting existing shareholders, to complete pivotal studies and commercial launches. ^[44]

For these reasons, IVVD remains a high‑volatility biotech stock where price swings — both up and down — can be extreme.

Bottom line: why IVVD is everywhere on November 14, 2025

On November 14, 2025, Invivyd (IVVD) has become one of the most talked‑about healthcare names on trading desks and news feeds:

The stock is up roughly 40–60% in pre‑market trading, according to multiple outlets, after weeks of positive news about Q3 growth, VYD2311 clinical progress, and regulatory alignment with the FDA. ^[45]
There is no new corporate press release today, but earlier catalysts — combined with heavy short interest and bullish analyst targets — appear to be re‑rating the stock in real time. ^[46]

Whether this move proves to be the start of a longer re‑pricing or a short‑term squeeze will depend on how well Invivyd executes on:

PEMGARDA’s commercial opportunity, and
VYD2311’s ambitious goal of becoming a long‑lasting, non‑vaccine COVID‑19 antibody.

As always, this article is for information and news purposes only and does not constitute investment advice. Anyone considering IVVD should carefully review the company’s SEC filings, risk factors, and their own financial situation before making any trading or investment decisions.

💉 Can Invivyd ($IVVD) Protect the Most Vulnerable from COVID-19?